Literature DB >> 22591284

Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.

Marlon S Mathews1, Van Vo, En-Chung Shih, Genesis Zamora, Chung-Ho Sun, Steen J Madsen, Henry Hirschberg.   

Abstract

Breast-conservation surgery (BCS) is now utilized in patients with stage I and II invasive breast cancer. However, positive surgical margins are associated with recurrence, and therefore some form of localized postoperative therapy (radiation/chemotherapy) is necessary to eliminate remaining cancer cells. Existing modalities have significant treatment-limiting side effects; therefore, alternative forms of localized therapy need to be explored. We studied the ex vivo effects of photochemical internalization (PCI) using 4 chemotherapeutic agents: cisplatin, cisplatin analog [D prostanoid, DP], doxorubicin, and bleomycin) on 3 breast cancer cell lines: MCF-7, MDA-MB-435, and MDA-MB-231. Illumination was carried out using a 670-nm diode laser at 5 mW/cm2 following incubation in the photosensitizer with aluminum phthalocyanine disulfonate. Toxicity was investigated using colony-forming assays and the mechanism of cell death was determined using Annexin flow-cytometry. We found that toxicity of DP and bleomycin was significantly enhanced by PCI compared with drug alone but was unchanged for cisplatin and doxorubicin. PCI treatment caused a decrease in the percentage of viable cells, predominantly by enhancing apoptosis. The action was synergistic across all 3 cell lines tested for DP and bleomycin. Thus, with appropriate delivery devices and choice of chemotherapeutic agents, PCI holds the promise of enhancing tumor cell toxicity surrounding the cavity of BCS resection sites and thereby decreasing local recurrence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591284      PMCID: PMC4124822          DOI: 10.1615/jenvironpatholtoxicoloncol.v31.i1.60

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol Oncol        ISSN: 0731-8898            Impact factor:   3.567


  55 in total

1.  Preliminary Results in 173 Breast Cancer Patients Treated with Post-Lumpectomy MammoSite Single-Lumen Brachytherapy or Multi-Catheter Brachytherapy.

Authors:  Richard B Wilder; Lisa D Curcio; Rajesh K Khanijou; Martin E Eisner; Jane L Kakkis; Lucy Chittenden; Jeffrey Agustin; Jessica Lizarde; Albert V Mesa; Jorge C Macedo; John Ravera; Kenneth M Tokita
Journal:  Breast J       Date:  2010 Nov-Dec       Impact factor: 2.431

2.  Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands.

Authors:  Radim Vrzal; Pavel Starha; Zdenek Dvorák; Zdenek Trávnícek
Journal:  J Inorg Biochem       Date:  2010-07-31       Impact factor: 4.155

Review 3.  Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy.

Authors:  Harry D Bear
Journal:  Surg Oncol Clin N Am       Date:  2010-07       Impact factor: 3.495

4.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.

Authors:  L D Mayer; M B Bally; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1986-05-09

5.  Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.

Authors:  Hyo Sook Han; Isildinha M Reis; Wei Zhao; Katsumasa Kuroi; Masakazu Toi; Eiji Suzuki; Rachel Syme; Louis Chow; Adrian Y S Yip; Stefan Glück
Journal:  Eur J Cancer       Date:  2011-07-07       Impact factor: 9.162

6.  Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.

Authors:  Y Madarnas; S F Dent; S F Husain; A Robinson; S Alkhayyat; W M Hopman; J L Verreault; T Vandenberg
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

7.  Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells.

Authors:  Pål K Selbo; Anette Weyergang; Anette Bonsted; Stephen G Bown; Kristian Berg
Journal:  J Pharmacol Exp Ther       Date:  2006-08-10       Impact factor: 4.030

8.  EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells.

Authors:  B P Fox; R P Kandpal
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

9.  High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.

Authors:  S Ostrow; M Egorin; J Aisner; N Bachur; P H Wiernik
Journal:  Cancer Clin Trials       Date:  1980

10.  CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration.

Authors:  Ke Zen; Dan-Qing Liu; Ya-Lan Guo; Chen Wang; Jun Shan; Ming Fang; Chen-Yu Zhang; Yuan Liu
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

View more
  2 in total

Review 1.  Nanoparticle-mediated drug delivery for treating melanoma.

Authors:  Vaibhav Mundra; Wei Li; Ram I Mahato
Journal:  Nanomedicine (Lond)       Date:  2015-08-05       Impact factor: 5.307

2.  Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models.

Authors:  Alejandra Martinez de Pinillos Bayona; Josephine H Woodhams; Hayley Pye; Rifat A Hamoudi; Caroline M Moore; Alexander J MacRobert
Journal:  Cancer Lett       Date:  2017-02-20       Impact factor: 8.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.